Colchicine After Electrocardioversion for Atrial Fibrillation

PHASE3RecruitingINTERVENTIONAL
Enrollment

416

Participants

Timeline

Start Date

April 14, 2024

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2027

Conditions
Atrial FibrillationCardiac Arrhythmia
Interventions
DRUG

Colchicine

"Colchicine 0.5 mg (oral) once daily for 90 days. The chemical name for colchicine is (S)-N-(5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9 oxobenzol\[a\]heptalen-7-yl) acetamide.~Colchicine consists of pale yellow scales or powder. It is soluble in water, freely soluble in alcohol, and slightly soluble in ether."

DRUG

Placebo

Matched placebo. Both the active drug and placebo will look similarly. The route and mode of administration is also similar to the active group.

Trial Locations (8)

1011

RECRUITING

Lausanne University Hospital, Lausanne

3010

RECRUITING

University Hospital Bern, Bern

4031

RECRUITING

University Hospital Basel, Basel

4101

RECRUITING

Cantonal Hospital Baselland (KSBL), Bruderholz

4310

RECRUITING

Herzpraxis am Rhein, Rheinfelden

4500

RECRUITING

Solothurner Spitäler AG, Solothurn

4600

RECRUITING

Cantonal Hospital Olten, Olten

6000

RECRUITING

Lucerne Cantonal Hospital, Lucerne

All Listed Sponsors
collaborator

Swiss Heart Foundation

OTHER

collaborator

Fondation Machaon, Switzerland, Genf

UNKNOWN

collaborator

Foundation for Cardiovascular Research Basel

UNKNOWN

lead

University Hospital, Basel, Switzerland

OTHER